Illumina (BSP:I1LM34) Tax Provision : R$-272 Mil (TTM As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Illumina Tax Provision?

Illumina's tax provision for the three months ended in Sep. 2024 was R$-83 Mil. Its tax provision for the trailing twelve months (TTM) ended in Sep. 2024 was R$-272 Mil.

Illumina Tax Provision Historical Data

The historical data trend for Illumina's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina Tax Provision Chart

Illumina Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Provision

Get a 7-Day Free Trial

-525.38

-1,028.94

-689.90

-356.69

-215.59

Illumina Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Tax Provision	Get a 7-Day Free Trial															138.28	-39.20	-84.66	-64.63	-83.07

Illumina Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-272 Mil.

Illumina Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Illumina Inc (BSP:I1LM34) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

ILMN:USA ILMN:Mexico 1ILMN:Italy 0J8Z:UK ILU:Germany ILU:Germany ILU:Germany ILMN:Austria

Address

5200 Illumina Way, San Diego, CA, USA, 92122

Website

https://www.illumina.com

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Illumina Headlines

No Headlines